QuidelOrtho Corporation has announced its intention to acquire full ownership of LEX Diagnostics following the anticipated 510(k) clearance by the U.S. FDA. The transaction, valued at approximately $100 million at closing, signifies a strategic shift in QuidelOrtho's molecular diagnostics strategy. As part of this realignment, QuidelOrtho plans to discontinue the development of its Savanna® platform. This move aims to strengthen the company's presence in the rapidly growing point-of-care molecular diagnostics segment. The announcement was made by Brian J. Blaser, President and CEO of QuidelOrtho, who highlighted the performance advantages and growth opportunities offered by LEX Diagnostics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.